Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
30 Mar 22
Current reports
8-K
Results of Operations and Financial Condition
9 Apr 24
8-K
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
28 Mar 24
8-K
Agile Therapeutics Announces Delisting from Nasdaq
25 Mar 24
8-K
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
14 Mar 24
8-K
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
23 Feb 24
8-K
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
15 Feb 24
8-K
Other Events
6 Dec 23
8-K
Entry into a Material Definitive Agreement
4 Dec 23
8-K
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
23 Feb 24
424B5
Prospectus supplement for primary offering
23 Feb 24
S-1/A
IPO registration (amended)
7 Feb 24
S-1/A
IPO registration (amended)
5 Feb 24
S-1/A
IPO registration (amended)
2 Feb 24
S-1/A
IPO registration (amended)
20 Dec 23
S-1
IPO registration
11 Dec 23
S-8
Registration of securities for employees
9 Jun 23
424B5
Prospectus supplement for primary offering
25 May 23
424B5
Prospectus supplement for primary offering
25 May 23
Proxies
DEF 14A
Definitive proxy
28 Apr 23
DEF 14A
Definitive proxy
9 Feb 23
PRE 14A
Preliminary proxy
26 Jan 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEF 14A
Definitive proxy
28 Mar 22
PRE 14A
Preliminary proxy
18 Mar 22
DEF 14A
Definitive proxy
2 Dec 21
PRE 14A
Preliminary proxy
22 Nov 21
DEFA14A
Additional proxy soliciting materials
23 Apr 21
Other
EFFECT
Notice of effectiveness
23 May 23
CORRESP
Correspondence with SEC
19 May 23
CORRESP
Correspondence with SEC
19 May 23
UPLOAD
Letter from SEC
19 Apr 23
EFFECT
Notice of effectiveness
5 Jul 22
CORRESP
Correspondence with SEC
29 Jun 22
CORRESP
Correspondence with SEC
29 Jun 22
CORRESP
Correspondence with SEC
29 Jun 22
UPLOAD
Letter from SEC
20 May 22
EFFECT
Notice of effectiveness
15 Oct 20
Ownership
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
4
Scott M Coiante
4 Oct 23
3
Scott M Coiante
25 Aug 23
4
Amy Welsh
30 Jun 23
4
Paul Korner
30 Jun 23
4
ALFRED ALTOMARI
30 Jun 23
4
Robert G Conway
30 Jun 23
4
Geoffrey Gilmore
30 Jun 23
4
Josephine Torrente
9 Jun 23